RU2002111355A - 5BETA-SAPOGENIN AND PSEUDOSAPOGENIN DERIVATIVES AND THEIR APPLICATION FOR TREATMENT OF DEMENTIA - Google Patents

5BETA-SAPOGENIN AND PSEUDOSAPOGENIN DERIVATIVES AND THEIR APPLICATION FOR TREATMENT OF DEMENTIA

Info

Publication number
RU2002111355A
RU2002111355A RU2002111355/04A RU2002111355A RU2002111355A RU 2002111355 A RU2002111355 A RU 2002111355A RU 2002111355/04 A RU2002111355/04 A RU 2002111355/04A RU 2002111355 A RU2002111355 A RU 2002111355A RU 2002111355 A RU2002111355 A RU 2002111355A
Authority
RU
Russia
Prior art keywords
optionally substituted
substituted alkyl
alkoxycarbonyl
carbamoyl
group
Prior art date
Application number
RU2002111355/04A
Other languages
Russian (ru)
Other versions
RU2325396C2 (en
Inventor
Пол БАРРАКЛУ
Джим ХЭНСОН
Фил Ганнинг
Дэрил РИЗ
Зонгкин Ксиа
Яэр Ху
Original Assignee
Фитофарм Плк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9923076.5A external-priority patent/GB9923076D0/en
Application filed by Фитофарм Плк filed Critical Фитофарм Плк
Publication of RU2002111355A publication Critical patent/RU2002111355A/en
Application granted granted Critical
Publication of RU2325396C2 publication Critical patent/RU2325396C2/en

Links

Claims (15)

1. Производные сапогенина общей формулы I или II:1. Derivatives of sapogenin of General formula I or II:
Figure 00000001
Figure 00000001
Figure 00000002
Figure 00000002
 а также их стереоизомеры и рацемические смеси, их фармацевтически приемлемые пролекарства и соли,as well as their stereoisomers and racemic mixtures, their pharmaceutically acceptable prodrugs and salts, где в общей формуле (I) R1, R2, R3, R4, R5, R6, R7, R8, R10, независимо друг от друга, представляют собой Н, ОН, =O или OR, где R - необязательно замещенный алкил, необязательно замещенный ацил, необязательно замещенный карбамоил или алкоксикарбонил;where in the General formula (I) R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 10 , independently from each other, represent H, OH, = O or OR, where R is optionally substituted alkyl, optionally substituted acyl, optionally substituted carbamoyl or alkoxycarbonyl; R9, R11, R12, R13 представляют собой Н, ОН или OR, где R - необязательно замещенный алкил, необязательно замещенный ацил, необязательно замещенный карбамоил или алкоксикарбонил;R 9 , R 11 , R 12 , R 13 represent H, OH or OR, where R is optionally substituted alkyl, optionally substituted acyl, optionally substituted carbamoyl or alkoxycarbonyl; R14 - необязательно замещенная алкильная группа,R 14 is an optionally substituted alkyl group,
Figure 00000003
означает необязательно двойную связь, кроме тех случаев, когда одновременно - R1=R2=R4=R5=R6=R7=R8=R9=R10=R11=R12=R13=Н,
Figure 00000003
means optionally a double bond, except when, at the same time, R 1 = R 2 = R 4 = R 5 = R 6 = R 7 = R 8 = R 9 = R 10 = R 11 = R 12 = R 13 = H, R3=βOH, R14=СН3, метальная группа в С22 является α-группой, С20 является α-группой, a C25 обладает S-конфигурацией,R 3 = βOH, R 14 = CH 3 , the methyl group in C22 is an α-group, C20 is an α-group, and C25 has an S-configuration, и где в общей формуле (II)and where in the general formula (II) R1, R2, R3, R4, R5, R6, R7, R8, R10, независимо друг от друга, представляют собой Н, ОН,=O или OR, где R - необязательно замещенный алкил, необязательно замещенный ацил, необязательно замещенный карбамоил или алкоксикарбонил;R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 10 , independently of each other, are H, OH, = O or OR, where R is optionally substituted alkyl, optionally substituted acyl, optionally substituted carbamoyl or alkoxycarbonyl; R9, R11, R12, R13 представляют собой Н, ОН или OR, где R - необязательно замещенный алкил, необязательно замещенный ацил, карбамоил или алкоксикарбонил;R 9 , R 11 , R 12 , R 13 are H, OH or OR, where R is optionally substituted alkyl, optionally substituted acyl, carbamoyl or alkoxycarbonyl; R14 - необязательно замещенная алкильная группа;R 14 is an optionally substituted alkyl group; R15=Н, необязательно замещенный алкил, необязательно замещенный ацил или глюкозил;R 15 = H, optionally substituted alkyl, optionally substituted acyl or glucosyl;
Figure 00000004
означает необязательно двойную связь.
Figure 00000004
means optionally a double bond. 2. Соединения по п.1, где в общей формуле (I) R4, R9, R12, R13=Н, R1, R2, R3, R5, R6, R7, R8, R10, независимо друг от друга, представляют собой Н, ОН, =O или OR, где R - необязательно замещенный алкил, необязательно замещенный ацил, карбамоил или алкоксикарбонил, R11=Н, ОН или OR, где R - необязательно замещенный алкил, необязательно замещенный ацил, карбамоил или алкоксикарбонил, R14 - алкильная группа, означает необязательно двойную связь, кроме тех случаев, когда одновременно R1=R2=R4=R5=R6=R7=R8=R9=R10=R11=R12=R13=Н, R3=βOH, R14=СН3, метильная группа в С22 является α-группой, С20 является α-группой, a C25 обладает S-конфигурацией.2. The compounds according to claim 1, where in the General formula (I) R 4 , R 9 , R 12 , R 13 = H, R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 10 , independently of one another, are H, OH, = O or OR, where R is optionally substituted alkyl, optionally substituted acyl, carbamoyl or alkoxycarbonyl, R 11 = H, OH or OR, where R is optionally substituted alkyl, optionally substituted acyl, carbamoyl or alkoxycarbonyl, R 14 is an alkyl group, means an optionally double bond, except when R 1 = R 2 = R 4 = R 5 = R 6 = R 7 = R 8 = R 9 = R 10 = R 11 = R 12 = R 13 = H, R 3 = βOH, R 14 = CH3, the methyl group at C22 is α-c ppoy, a C20 α-group, a C25 has S-configuration. 3. Соединения по п.1 или 2, где в общей формуле (I) R1=R2=R4=R5=R6=R7=R8=R9=R10=R11=R12=R13=Н, R3=Н, -ОН, -ОМе, -ОСОСН3, =O, -O-CO-OEt или -O-СО-(СН2)2-CO2Н, R14=СН3 кроме тех случаев, когда одновременно R1=R2=R4=R5=R6=R7=R8=R9=R10=R11=R12=R13=Н, R3=βOH, R14=СН3, С25 обладает S-конфигурацией, С20 является α-группой и метальная группа в С22 является α-группой.3. The compounds according to claim 1 or 2, where in the General formula (I) R 1 = R 2 = R 4 = R 5 = R 6 = R 7 = R 8 = R 9 = R 10 = R 11 = R 12 = R 13 = H, R 3 = H, —OH, —Ome, —OOCCH 3 , = O, —O — CO — OEt, or —O — CO— (CH 2 ) 2 —CO 2 H, R 14 = CH 3 except in cases where at the same time R 1 = R 2 = R 4 = R 5 = R 6 = R 7 = R 8 = R 9 = R 10 = R 11 = R 12 = R 13 = N, R 3 = βOH, R 14 = CH 3 , C25 has an S-configuration, C20 is an α-group and the methyl group in C22 is an α-group. 4. Соединения по любому из предыдущих пунктов, где в общей формуле (II) R4, R9, R12, R13=Н, R1, R2, R3, R5, R6, R7, R8, R10, независимо друг от друга, представляют собой Н, ОН, =O или OR, где R необязательно замещенный алкил, необязательно замещенный ацил, карбамоил или алкоксикарбонил, R11=Н, ОН или OR, где R - необязательно замещенный алкил, необязательно замещенный ацил, карбамоил или алкоксикарбонил, R14 - необязательно замещенная алкильная группа, R15=Н, необязательно замещенный алкил, необязательно замещенный ацил или глюкозил,4. Compounds according to any one of the preceding paragraphs, where in the General formula (II) R 4 , R 9 , R 12 , R 13 = H, R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 10 , independently of one another, are H, OH, = O or OR, where R is optionally substituted alkyl, optionally substituted acyl, carbamoyl or alkoxycarbonyl, R 11 = H, OH or OR, where R is optionally substituted alkyl, optionally substituted acyl, carbamoyl or alkoxycarbonyl, R 14 is an optionally substituted alkyl group, R 15 = H, optionally substituted alkyl, optionally substituted acyl or glucosyl,
Figure 00000005
означает необязательно двойную связь.
Figure 00000005
means optionally a double bond. 5. Соединения по любому из предыдущих пунктов, отличающиеся тем, что они выбраны из следующих:5. Compounds according to any one of the preceding paragraphs, characterized in that they are selected from the following:
Figure 00000006
Figure 00000006
Figure 00000007
Figure 00000007
 6. Применение соединений по любому из предыдущих пунктов в производстве лекарства для повышения числа мускариновых рецепторов или усиления функции мускариновых рецепторов у человека или животных.6. The use of compounds according to any one of the preceding paragraphs in the manufacture of a medicament for increasing the number of muscarinic receptors or enhancing the function of muscarinic receptors in humans or animals. 7. Применение по п.6, в котором указанное лекарство служит для лечения нарушений когнитивных функций.7. The use according to claim 6, in which the specified medicine is used to treat cognitive impairment. 8. Применение по п.6 или 7, в котором указанное лекарство служит для улучшения когнитивных функций у пациентов, страдающих от связанных с возрастом нарушений когнитивных функций.8. The use according to claim 6 or 7, in which the specified medicine is used to improve cognitive function in patients suffering from age-related cognitive impairment. 9. Применение по любому из пп.6, 7 или 8, в котором указанное лекарство служит для лечения болезни, выбранной из числа болезни Альцгеймера, старческой деменции по типу Альцгеймера, болезни Паркинсона, деменции, сопровождающейся изменениями в тельцах Льюиса, постуральной (ортостатической) гипотензии, аутизма, синдрома хронического утомления, миастении Gravis, болезни Ламберта-Итона (Lambert Eaton), болезней и недомоганий, связанных с синдромом войны в Персидском заливе, профессионального воздействия фосфоорганических соединений и недомоганий, связанных с возрастом.9. The use according to any one of claims 6, 7 or 8, wherein said medicine is used to treat a disease selected from among Alzheimer's disease, senile dementia of the Alzheimer's type, Parkinson's disease, dementia, accompanied by changes in Lewis bodies, postural (orthostatic) hypotension, autism, chronic fatigue syndrome, Gravis myasthenia gravis, Lambert Eaton disease, diseases and ailments associated with the Gulf War syndrome, professional exposure to organophosphorus compounds and ailments s age. 10. Применение по любому из пп.6-9, в котором указанное лекарство служит для лечения заболеваний, отличающихся наличием нейрофибриллярных клубков и/или β-амилоидных бляшек.10. The use according to any one of claims 6 to 9, wherein said drug is used to treat diseases characterized by the presence of neurofibrillary tangles and / or β-amyloid plaques. 11. Применение по любому из пп.6-10, в котором указанное лекарство служит для лечения болезни Альцгеймера или старческой деменции по типу Альцгеймера.11. The use according to any one of claims 6 to 10, wherein said drug is used to treat Alzheimer's disease or senile dementia of the Alzheimer's type. 12. Фармацевтическая композиция, обладающая свойством усиления когнитивных функций, включающая фармакологически эффективное количество производного сапогенина формулы (I) или (II) по любому из пп.1-5.12. A pharmaceutical composition having the property of enhancing cognitive functions, comprising a pharmacologically effective amount of a sapogenin derivative of formula (I) or (II) according to any one of claims 1 to 5. 13. Фармацевтическая композиция, обладающая свойством усиления когнитивных функций, включающая фармакологически эффективное количество производного сапогенина формулы (I) или (II) по любому из пп.1-5 в виде экстракта, полученного из растения рода Smilax, Asparagus, Anemarrhena, Yucca или Agave.13. A pharmaceutical composition having the property of enhancing cognitive functions, comprising a pharmacologically effective amount of a sapogenin derivative of formula (I) or (II) according to any one of claims 1 to 5 in the form of an extract obtained from a plant of the genus Smilax, Asparagus, Anemarrhena, Yucca or Agave . 14. Способ усиления когнитивных функций у человека или животных, включающий введение эффективной дозы производного сапогенина формулы (I) или (II) по любому из пп.1-5.14. A method of enhancing cognitive functions in humans or animals, comprising administering an effective dose of a sapogenin derivative of formula (I) or (II) according to any one of claims 1 to 5. 15. Применение производного сапогенина формулы (I) или (II) по любому из пп.1-5 в пищевых продуктах или напитках для усиления когнитивных функций.15. The use of a sapogenin derivative of the formula (I) or (II) according to any one of claims 1 to 5 in foods or drinks to enhance cognitive function.
RU2002111355/04A 1999-09-29 2000-09-29 Derivatives of 5b-sapogenin and pseudo sapogenin and application for dementia medical treatment RU2325396C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9923076.5A GB9923076D0 (en) 1999-09-29 1999-09-29 Sapogenin derivatives and their use
GB9923076.5 1999-09-29

Publications (2)

Publication Number Publication Date
RU2002111355A true RU2002111355A (en) 2003-12-20
RU2325396C2 RU2325396C2 (en) 2008-05-27

Family

ID=10861837

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002111355/04A RU2325396C2 (en) 1999-09-29 2000-09-29 Derivatives of 5b-sapogenin and pseudo sapogenin and application for dementia medical treatment

Country Status (27)

Country Link
US (2) US7138427B2 (en)
EP (2) EP1224205B1 (en)
JP (1) JP2003510332A (en)
KR (1) KR100771491B1 (en)
CN (2) CN101411712A (en)
AT (1) ATE325808T1 (en)
AU (1) AU778294C (en)
BR (1) BR0014381A (en)
CA (2) CA2640998A1 (en)
CY (1) CY1105225T1 (en)
CZ (1) CZ300150B6 (en)
DE (1) DE60027913T2 (en)
DK (1) DK1224205T3 (en)
ES (1) ES2260055T3 (en)
GB (1) GB9923076D0 (en)
HK (1) HK1045525B (en)
HR (2) HRP20020255A2 (en)
IL (2) IL148920A0 (en)
MX (1) MXPA02003305A (en)
NO (1) NO324959B1 (en)
NZ (1) NZ518596A (en)
PT (1) PT1224205E (en)
RU (1) RU2325396C2 (en)
TR (1) TR200200821T2 (en)
UA (1) UA82978C2 (en)
WO (1) WO2001023406A1 (en)
ZA (1) ZA200202382B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
PT1490071E (en) * 2002-03-27 2009-05-25 Phytopharm Plc Therapeutic uses of sapogenins
AU2003229877B8 (en) * 2002-03-27 2008-06-12 Phytopharm Plc Theraputic methods and uses of sapogenins and their derivatives
NZ547897A (en) * 2002-03-27 2008-02-29 Phytopharm Plc Therapeutic methods and uses of sapogenins and their derivatives
ATE459636T1 (en) * 2002-10-28 2010-03-15 Phytopharm Plc STEREOSPECIFIC REDUCTION OF SAPOGEN-3-ONES
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20080182801A1 (en) * 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
GB0424528D0 (en) 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
KR20110115589A (en) 2009-01-24 2011-10-21 파이토팜 피엘씨 Treatment of neurotrophic factor mediated disorders
CN101768202B (en) * 2009-02-18 2013-10-30 沈阳药科大学 Preparing method of high purity sarsasapogenin in rhizoma anemarrhenae and derivatives thereof, and medical new application thereof
EP2595621A1 (en) 2010-07-20 2013-05-29 Phytopharm PLC Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders
CU20110244A7 (en) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem SPI-ESTEROID SYSTEMS WITH NEUROACTIVE AND ANTI-INFLAMMATORY EFFECTS
US11319338B2 (en) 2012-04-03 2022-05-03 Goldporp Pharma Limited Timosaponin compounds
CN102924559B (en) * 2012-11-16 2015-10-28 沈阳药科大学 Sarsasapogenin derivative and Synthesis and applications thereof
GB201305708D0 (en) * 2013-03-28 2013-05-15 Clasado Inc Novel use
CN103232520A (en) * 2013-05-13 2013-08-07 中国药科大学 Spirosteroid compounds and preparation method and medical application thereof
CN106905407B (en) * 2015-01-27 2019-08-13 华东理工大学 The derivative of Sarsasapogenin structural modification, its pharmaceutical composition and its application
CA3001510C (en) * 2015-10-29 2022-05-24 Emmyon, Inc. Furostan-3-ol derivatives as skeletal muscle hypertrophic agents
CN106977581B (en) * 2017-04-17 2021-01-01 华东理工大学 Application of derivative modified by timosaponin structure and pharmaceutical composition

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB852847A (en) 1958-03-04 1960-11-02 British Drug Houses Ltd Improvements in or relating to 6-methyl steroid compounds
US3575810A (en) * 1967-07-19 1971-04-20 Takashi Matsushima Method for removal of side chain of sapogenins
BE794362A (en) * 1972-01-22 1973-07-23 Merck Patent Gmbh WATER-SOLUBLE STERINE SULPHATES
US3929769A (en) * 1972-05-19 1975-12-30 Ciba Geigy Corp Process for the manufacture of steroid epoxides
CA985172A (en) * 1972-10-06 1976-03-09 Dushan M. Dvornik Compositions and methods for reducing blood cholesterol
DE2416978A1 (en) * 1974-04-08 1975-10-09 Degussa MEDICINAL PRODUCTS WITH THE MAIN APOGNANT OF THE HELLEBORUS SPECIES AS THE ACTIVE SUBSTANCE
LU81256A1 (en) * 1979-05-15 1980-12-16 Oreal HAIR COSMETIC COMPOSITION, IN PARTICULAR FOR WASHING AND / OR UNMAKING HAIR, BASED ON AN EXTRACT OF PLANTS CONTAINING SAPONOSIDES
IT1144136B (en) 1980-03-05 1986-10-29 Zenyaku Kogyo Kk GLUCOSIDES OF CONDUCT ANTI-CANCER AGENTS INCLUDING THEM AND PROCEDURE FOR THEIR PREPARATION
GB2097672A (en) 1981-05-01 1982-11-10 Pattni Ramesh Damji Devji Process for extraction of crude sapogenins from Agave Leaves
JPS5855500A (en) * 1981-09-25 1983-04-01 Tokiwa Yakuhin Kogyo Kk Preparation of 16-dehydropregnenolone
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4562250A (en) * 1982-09-13 1985-12-31 Regents Of The University Of Minnesota Steroidal glycosides produced by Yucca tissue culture
US4546097A (en) * 1983-11-04 1985-10-08 The United States Of America As Represented By The Department Of Health And Human Services Saponin-based polyether polyols, pharmaceutical compositions and a method of using same
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
JPS62234025A (en) 1986-04-03 1987-10-14 Asahi Chem Ind Co Ltd Food for senile dementia
US5017562A (en) * 1987-02-11 1991-05-21 Regents Of The University Of Minnesota Crystalline saponin-containing complex
DE3838716A1 (en) * 1988-11-15 1990-05-17 Kanoldt Arzneimittel Gmbh MEDICINAL PRODUCTION OF ESTER DERIVATIVES OF HECOGENINE AND ITS USE FOR THE TREATMENT OF BENIGNER PROSTATE HYPERPLASIA
JPH02188528A (en) 1989-01-13 1990-07-24 Tsurataka Tashiro Remedy for dementia
BR9105952A (en) * 1990-01-18 1992-11-17 Cura Nominees Pty Ltd METHOD FOR IDENTIFYING COMPOUND AND TO CONTROL CELLULAR AUTOPHAGY, MOBILE CELLULAR IMMOBILIZATION, CELLULAR IMMOBILIZATION, CANCER TREATMENT METHOD, CONTRACEPTION, PREGNANCY TERMINATION, REMOVAL OF ORGANIZATION, PATHOGENIC AND DEVELOPMENTAL COSTS IN AN ANIMAL BODY, METHOD OF MARKING AND IDENTIFYING TARGET CELL, COMPOUND AND COMPOSITION CONTAINING AT LEAST ONE COMPOUND TO CONTROL CELL AUTOPHAGY, AGGUUTINATION OR IMMOBILIZATION OF MOBILE CELLS
SE9100342D0 (en) 1991-02-04 1991-02-04 Astra Ab NOVEL STEROID ESTERS
US5252729A (en) * 1991-10-23 1993-10-12 Schering Corporation Extraction of compounds from plant materials using supercritical fluids
US5244887A (en) * 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
JPH05246866A (en) * 1992-03-06 1993-09-24 Ruibosuteii Japan:Kk Agent for stimulating cerebral metabolism and for improving cerebral function
CZ331094A3 (en) * 1992-06-26 1995-09-13 Pfizer Steroidal glycosides and their use for treating hypercholesterolemia and atherosclerosis
DE4303214A1 (en) * 1993-02-04 1994-08-11 Wolfgang Marks Treatment of diseases of viral, viroidal or oncogenic origin by steroid saponins or their aglycones
WO1994018994A1 (en) 1993-02-23 1994-09-01 Pharmakon Usa, Inc. Therapeutic herbal composition
CN1092992A (en) 1993-03-29 1994-10-05 中国科学院沈阳应用生态研究所 Improve medicine of brain function and preparation method thereof
CN1052636C (en) 1993-03-29 2000-05-24 中国科学院沈阳应用生态研究所 Medicine for raising brains function and its preparing method
JPH06305952A (en) 1993-04-27 1994-11-01 Sumitomo Pharmaceut Co Ltd Threo-3-(3,4-dihydroxyphenyl)serine nasotracheal administration pharmaceutical preparation
CA2161239A1 (en) * 1993-04-28 1994-11-10 Douglas J.M. Allen Spirostanyl glycosidal crystalline monohydrate
CN1033754C (en) * 1993-05-31 1997-01-08 上海第二医科大学 Medicine with regulating effect on beta adrenergic receptor and M-cholinergic receptor and preparation thereof
CN1102186A (en) 1993-10-29 1995-05-03 沈阳医学院 Determination and usage of new component of traditional Chinese medicine Chinese onion
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
EP0737203A1 (en) * 1993-12-28 1996-10-16 Pfizer Inc. Steroidal glycosides
JPH09500906A (en) * 1993-12-28 1997-01-28 ファイザー・インク． Blood cholesterol lowering drugs
IL109614A (en) 1994-05-10 1998-06-15 Yissum Res Dev Co Comestible products containing saponins
US5563131A (en) 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US5840740A (en) 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
PL318937A1 (en) * 1994-08-30 1997-07-21 Pfizer Spirostanyloglycoside crystals
MX9702175A (en) 1994-09-20 1997-06-28 Pfizer Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor.
US6150336A (en) * 1995-05-29 2000-11-21 Pfizer Inc. Steroidal glycosides
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
JPH09100295A (en) 1995-06-13 1997-04-15 Toray Ind Inc Novel triterpenoid saponin and therapeutic agent containing the same as active ingredient and having action of extendingneurite
CU22860A1 (en) 1995-10-12 2003-05-26 Univ La Habana SPIROSTANONES WITH OXYGEN FUNCTIONS IN RING A. AS REGULATORS OF VEGETABLE GROWTH AND ITS PROCEDURE OF OBTAINING
US6130232A (en) 1995-10-13 2000-10-10 Banyu Pharmaceutical Coaltd Substituted piperidine derivatives as muscarinic M3 receptor antagonists
FR2743561B1 (en) 1996-01-15 1998-02-20 Fournier Sca Lab STEROID DERIVATIVES, METHOD OF PREPARATION AND THERAPEUTIC USE
KR0169536B1 (en) 1996-02-27 1999-01-15 손경식 Novel ginseng saponins, process for preparation thereof and anti-tumor agents containing the same as an active ingredient
US5726179A (en) 1996-04-01 1998-03-10 The University Of Toledo Muscarinic agonists
JP4228116B2 (en) 1996-05-09 2009-02-25 ゼニス・オペレイションズ・プロプライエタリー・リミテッド Treatment of asthma and airway diseases
EP0930876B2 (en) 1996-07-22 2010-07-07 Renovo Limited Use of compounds that promote oestrogenic activity for acclerating the healing of skin wounds
US5804239A (en) * 1996-07-26 1998-09-08 Nouveau Technologies, Inc. Method and composition for food flavoring
EP1019044B1 (en) 1997-05-15 2007-04-11 University of Washington Composition and methods for treating alzheimer's disease and other amyloidoses
AU7979998A (en) 1997-06-20 1999-01-04 University Of Utah Research Foundation Use of plant-alkaloids to enhance innate immunity defense mechanisms
CN1268027A (en) 1997-08-28 2000-09-27 Cv技术公司 Chemical and pharmacological standardization of herbal extracts
JP3906948B2 (en) * 1997-09-13 2007-04-18 本田技研工業株式会社 Shift control device for electric transmission
CN1131237C (en) * 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 Usage of steroi saponin for preventing and curing senile dementia and new steroid saponin
CA2217088A1 (en) 1997-09-30 1999-03-30 Universite De Sherbrooke New mandevilla velutina derivatives as steady-state r-type ca2+ channel blockers, method of making and use thereof
JP3873097B2 (en) * 1997-11-06 2007-01-24 独立行政法人理化学研究所 Anti-obesity agent and lipid metabolism improving agent
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9905275D0 (en) * 1999-03-08 1999-04-28 Phytopharm Ltd Treatment of conditions associated with membrane-bound receptors and their function
HUP0101693A3 (en) * 1998-03-26 2002-08-28 Phytopharm Plc Godmanchester Use of steroidal sapogenins and their derivatives for producing pharmaceutical compositions for the treatment of alzheimeirs disease
KR100292406B1 (en) * 1998-06-11 2001-07-12 윤종용 Photosensitive polymer and dissolution inhibitor for chemically amplified photoresist and chemically amplified photoresist composition having thereof
GB2347676A (en) 1999-03-08 2000-09-13 Phytopharm Plc Screening method
GB9923078D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AUPP968699A0 (en) 1999-04-09 1999-05-06 Cura Nominees Pty Ltd Therapeutic compositions and method for their preparation
US6544566B1 (en) 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
GB9923077D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
BR0001794A (en) * 2000-05-15 2001-12-26 Laboratorios Biosintetica Ltda Application of phytosteroids (and their isomers), folic acid, cyanocobalamin and pyridoxine in dietary fibers (food)
US20050130948A1 (en) 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives

Similar Documents

Publication Publication Date Title
RU2002111355A (en) 5BETA-SAPOGENIN AND PSEUDOSAPOGENIN DERIVATIVES AND THEIR APPLICATION FOR TREATMENT OF DEMENTIA
ES2274013T3 (en) RECEIVER ACTIVATOR (S) COMBINATIONS ACTIVATED BY THE PROOFISER OF PEROXISOMES (PPAR) AND INHIBITOR (S) M OF THE ABSORPTION OF STELORS AND TREATMENTS FOR VASCULAR DISORDERS.
CN106102737B (en) Cromoglycic acid derivative and the correlation technique of imaging and treatment
US4888347A (en) Use of specific N-methyl-D-aspartate receptor antagonists in the prevention and treatment of neurodegeneration
JP2009543858A (en) Conjugates comprising psychotropic drugs or GABA agonists and organic acids and their use to treat pain and other CNS disorders
CO6361928A2 (en) MODULAR ARIL METHYL BENZOQUINAZOLINONA POSITIVE ALLOSTERICS OF THE RECEIVER M1
RU96118132A (en) COMPOUNDS ACTIVE IN THE NEW SITE ON THE RECEPTOR-REGULATED CALCIUM CHANNELS AND USED FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
CY1112399T1 (en) ACETYL-L-CARNITINE FOR PREVENTION AND / OR THALIDOMIDE CATALOG OF REGIONAL NEUROPATHIES
EA039629B1 (en) Pharmaceutical combination comprising a selective s1p1 receptor agonist
JPH11501282A (en) Epibatidine and its derivatives as cholinergic agonists and antagonists
KR20100132489A (en) Combination comprising paclitaxel for treating ovarian cancer
JP4377130B2 (en) Cryptotanshinone for the prevention and treatment of early Alzheimer's disease
CN109562097B (en) Progressive forms of andrographolide for treating multiple sclerosis
RU2007112950A (en) NEW DERIVATIVES OF 3,5-SECO-4-NORCHOLESTAN AND THEIR APPLICATION
CA1248454A (en) Cytidyl diphosphocholine-drug composition and process
JP2008517901A (en) Orally active cannabinoid analogues
EP0001924B2 (en) Pharmaceutical composition for administering choline
RU2017137008A (en) TOTALL-LIKE-RECEPTOR ANTAGONISTS 4 AND APPLICATION IN AUTOIMMUNE DISEASES OF THE LIVER
WO2010148300A1 (en) Methods of treatment of neurological disorders
AU2014352716A1 (en) Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits
JP7295145B2 (en) Medicaments and uses thereof for treating neurodegenerative diseases
US5652248A (en) Method of preventing peripheral neuropathies induced by anticancer agents
JP2022528481A (en) Pharmaceutical compositions of pimozide and methotrexate, and their use
CA2920073A1 (en) Boosting the effect of methotrexate through the combined use with lipophilic statins